IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Gwong-Jen J. Chang

Application No. 09/826,115

Filed: April 4, 2001

Confirmation No. 4134

For: NUCLEIC ACID VACCINES FOR PREVENTION OF FLAVIVIRUS INFECTION

Examiner: Jeffrey S. Parkin, Ph.D.

Art Unit: 1648

Attorney Reference No. 6395-64908-01

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AF, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent for Applicant(s) 

Date Mailed November 30, 2006

MAIL STOP AF
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

COPY

TRANSMITTAL LETTER

Submitted herewith for filing in the application referenced above are the following:

- ☒ Copy of Office communication dated September 27, 2006 (8 pages)
- ☒ Communication to the Examiner (1 page)
  - ☒ Exhibit A including:
    - ☒ Copy of Information Disclosure Statement submitted July 27, 2001 (2 pages)
    - ☒ Copy of Form 1449 (4 pages)
    - ☒ Copy of Return Postcard from PTO acknowledging receipt (1 page)
  - ☒ Exhibit B including:
    - ☒ Copy of Information Disclosure Statement submitted February 15, 2002 (2 pages)
    - ☒ Copy of Form 1449 (2 pages)
    - ☒ Copy of Return Postcard from PTO acknowledging receipt (1 page)

☒ Please update PTO records to reflect Attorney Reference No. 6395-64908-01.

☒ The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.

☒ Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

cc: Docketing

By 
Gwynedd Warren, Ph.D.
Registration No. 45,200

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Gwong-Jen J. Chang

Application No. 09/826,115

Filed: April 4, 2001

Confirmation No. 4134

For: NUCLEIC ACID VACCINES FOR PREVENTION OF FLAVIVIRUS INFECTION

Examiner: Jeffrey S. Parkin, Ph.D.

Art Unit: 1648

Attorney Reference No. 6395-64908-01

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AF, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent for Applicant(s)

Date Mailed November 30, 2006

MAIL STOP AF
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

COMMUNICATION TO THE EXAMINER

Enclosed as Exhibit A are copies of an Information Disclosure Statement ("IDS") and 1449 Form previously submitted in this application to the U.S. Patent and Trademark Office ("PTO") on July 27, 2001. Also enclosed as part of Exhibit A is a copy of the return postcard dated July 30, 2001, acknowledging receipt by the PTO of the IDS, 1449 Form, and accompanying paper copies of the references.

Enclosed as Exhibit B are copies of an IDS and 1449 Form previously submitted in this application to the PTO on February 15, 2002. Also enclosed as part of Exhibit B is a copy of the return postcard dated March 1, 2002, acknowledging receipt by the PTO of the IDS, 1449 Form, and accompanying paper copies of the references.

As a courtesy to the Examiner, a copy of this filing is being provided directly via facsimile number (571) 273-0908.

These documents are being submitted as evidence of the proper submission and receipt by the Patent and Trademark Office of the cited references. Copies of the cited references are available in electronic form in the related U.S. Patent Application No. 10/500,796. Applicants respectfully request consideration of the documents properly cited during prosecution of this application, and that these documents be listed as references cited on the issued patent.

Respectfully submitted,
KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

By
Gwynedd Warren, Ph.D.
Registration No. 45,200

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/826,115	04/04/2001	Gwong-Jen J. Chang	14114.0332U3	4134

46135 7590 09/27/2006

KLARQUIST SPARKMAN, LLP
121 S.W. SALMON STREET
SUITE 1600
PORTLAND, OR 97204

EXAMINER	
PARKIN, JEFFREY S	

ART UNIT	PAPER NUMBER
1648	

DATE MAILED: 09/27/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

PTO-90C (Rev. 10/03)

UNITED STATES DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.

EXAMINER	
ART UNIT	PAPER
	09202006

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

The information disclosure statements (IDSs) (dated 27 July, 2001, and 15 February, 2002) that accompanied the communication dated 03 February, 2006, fail to comply with 37 CFR 1.98(a)(2), which requires a legible copy of each cited foreign patent document; each non-patent literature publication or that portion which caused it to be listed; and all other information or that portion which caused it to be listed. It has been placed in the application file, but the information referred to therein has not been considered. Applicants state that these IDSs were provided earlier, however, no such electronic record of these documents is present. Additionally, none of the cited references were present in the electronic application. Applicants are invited to resubmit these IDSs along with the proper mailing documentation. Legible copies of each reference should also be provided pursuant to 37 CFR 1.98(a)(2). Applicants should clearly identify any documents that were submitted in an earlier filed copending application if they are not providing additional copies.

Jeffrey S. Parkin, Ph.D.
Primary Examiner
Art Unit: 1648

COPY

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 7-80) PATENT AND TRADEMARK OFFICE LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)	ATTORNEY DOCKET NO.: 14114.033203	SERIAL NO. 09/826,115
	APPLICANT: Chang	
	FILING DATE: April 4, 2001	GROUP: ~~Unassigned~~ 1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,514,375	05/07/96	Paoletti et al.	424	199.1	
	AB	5,494,671	02/27/96	Hoi et al.	424	218.1	
	AC	5,229,293	07/20/93	Matsuura et al.	435	320.1	
	AD	5,021,347	06/04/91	Yasui et al.	435	235	
	AE	4,810,492	03/07/89	Fujita et al.	424	88	

FOREIGN PATENT DOCUMENTS

	AF	WO 98/63095	12/09/98	PCT			
	AG	WO 93/06214	04/01/93	PCT			
	AH	WO 92/03545	03/05/92	PCT			
	AI	WO 90/01946	03/08/90	PCT			

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AJ	Abstract, Japanese Patent Publication No. JP 03276941 "Non-infective structure particle preparation, useful as vaccine - by infecting preliminary flavivirus infected cell with cDNA integrated recombinant vaccinia virus, and then separating non-infective structure particles containing E protein of flavivirus," (October 26, 1993)
	AK	Deubel et al., Nucleotide Sequence and Deduced Amino Acid Sequence of the Nonstructural Proteins of Dengue Type 2 Virus, Jamaica Genotype: Comparative Analysis of the Full-Length Genome. *Virol.* 165: 234-244 (1988)
	AL	Davis et al., West Nile Virus Recombinant DNA Vaccine Protects Mouse and Horse from Virus Challenge and Expresses in Vitro a Noninfectious Recombinant Antigen That Can Be Used in Enzyme-linked Immunosorbent Assays. *J. Virol.* 75(9): 4040-4047 (2001) (published on-line April 4, 2001)
	AM	Konishi et al., Generation and Characterization of a Mammalian Cell Line Continuously Expressing Japanese Encephalitis Virus Subviral Particles. *J. Virol.* 75(5): 2204-2212 (2001)
	AN	Asnis et al., The West Nile Virus Outbreak of 1999 in New York: The Flushing Hospital Experience. *Clin. Infect. Dis.* 30: 413-418 (2000)
	AO	Chang et al., A Single Intramuscular Injection of Recombinant Plasmid DNA Induces Protective Immunity and Prevents Japanese Encephalitis in Mice. *J. Virol.* 74(9):4244-4252 (2000)
	AP	Garmendia et al., Recovery and Identification of West Nile Virus from a Hawk in Winter. *J. Clin. Microbiol.* 38(8): 3110-3111 (2000)

COPY

	AQ	Johnson et al., Detection of Anti-Arboviral Immunoglobulin G by Using a Monoclonal Antibody-Based Capture Enzyme-Linked Immunosorbent Assay. *J. Clin. Microbiol.* 38(5): 1827-1831 (2000)
	AR	Martin et al., Standardization of Immunoglobulin M Capture Enzyme-Linked Immunosorbent Assays for Routine Diagnosis of Arboviral Infections. *J. Clin. Microbiol.* 38(5): 1823-1826 (2000)
	AS	Update: Surveillance for West Nile Virus in Overwintering Mosquitos --- New York, 2000. *Morb. Mortal. Wkly. Rep.* 49(09): 178-179 (Mar. 10, 2000)
	AT	Update: West Nile Virus Activity --- Northeastern United States, 2000. *Morb. Mortal. Wkly. Rep.* 49(36): 820-822 (Sept. 15, 2000)
	AU	Aberle et al., A DNA Immunization Model Study with Constructs Expressing the Tick-Borne Encephalitis Virus Envelope Protein E in Different Physical Forms. *J. Immunol.* 163: 6756-6761 (1999)
	AV	Anderson et al., Isolation of West Nile Virus from Mosquitoes, Crows, and a Cooper's Hawk in Connecticut. *Science* 286: 2331-2333 (Dec. 17, 1999)
	AW	Azevedo et al., Main features of DNA-based immunization vectors. *Braz. J. Med. Biol. Res.* 32(2): 147-153 (1999)
	AX	Jia et al., Genetic analysis of West Nile New York 1999 encephalitis virus. *Lancet* 354: 1971-1972 (Dec. 4, 1999)
	AY	Lanciotti et al., Origin of the West Nile Virus Responsible for an Outbreak of Encephalitis in the Northeastern United States. *Science* 286: 2333-2337 (Dec. 17, 1999)
	AZ	Mir et al., High-efficiency gene transfer into skeletal muscle mediated by electric pulses. *Proc. Nat. Acad. Sci. USA* 96: 4262-4267 (1999)
	BA	Ho et al. DNA vaccination induces a long-term antibody response and protective immunity against pseudorabies virus in mice. *Arch. Virol.* 143: 115-125 (1998)
	BB	Konishi et al., Induction of Protective Immunity against Japanese Encephalitis in Mice by Immunization with a Plasmid Encoding Japanese Encephalitis Virus Premembrane and Envelope Genes. *J. Virol.* 72(6):4925-4930 (June 1998)
	BC	Kuno et al., Phylogeny of the Genus *Flavivirus*. *J. Virol.* 72(1): 73-83 (Jan. 1998)
	BD	Lin et al., DNA Immunization with Japanese Encephalitis Virus Nonstructural Protein NS1 Elicits Protective Immunity in Mice. *J. Virol.* 72(1): 191-200 (Jan 1998)
	BE	Klinman et al., CpG motifs as immune adjuvants. *Vaccine* 17: 19-25 (1999)
	BF	Kochel et al. Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice. *Vaccine* 15(5): 547-552 (1997)
	BG	Wang et al., Immune Response to Neonatal Genetic Immunization. *Virology* 228: 278-284 (1997)
	BH	Dmitriev et al., Immunization with recombinant vaccinia viruses expressing structural and part of the nonstructural region of tick-borne encephalitis virus cDNA protect mice against lethal encephalitis. *J. Biotechnol.* 44: 97-103 (1996)
	BI	Hennessy et al., Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study. *Lancet* 347: 1583-1586 (1996)
	BJ	Phillpotts et al., Immunization with DNA polynucleotides protects mice against lethal challenge with St. Louis encephalitis virus. *Arch. Virol.* 141: 743-749 (1996)
	BK	Sato et al., Immunostimulatory DNA Sequences Necessary for Effective Intradermal Gene Immunization. *Science* 273: 352-354 (1996)
	BL	Allison et al., Synthesis and Secretion of Recombinant Tick-Borne Encephalitis Virus Protein E in Soluble and Particulate Form. *J. Virol.* 69(9): 5816-5820 (Sept 1995)
	BM	Chen et al., Construction of Intertypic Chimeric Dengue Viruses Exhibiting Type 3 Antigenicity and Neurovirulence for Mice. *J. Virol.* 69(8): 5186-5190 (Aug 1995)

COPY

	BN	dos Santos et al., Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213. *Virus Research* 35: 35-41 (1995)
	BO	Venugopal et al., Immunity to St. Louis encephalitis virus by sequential immunization with recombinant vaccinia and baculovirus derived PrM/E proteins. *Vaccine* 13(11): 1000-1005 (1995)
	BP	Mandl et al., Complete Genomic Sequence of Powassan Virus: Evaluation of Genetic Elements in Tick-Borne Versus Mosquito-Borne Flaviviruses. *Virology* 194: 173-184 (1993)
	BQ	Konishi et al., Mice Immunized with a Subviral Particle Containing the Japanese Encephalitis Virus prM/M and E Proteins Are Protected from Lethal JEV Infection. *Virology* 188: 714-720 (1992)
	BR	Wolff et al., Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. *Hum. Mol. Genet.* 1(6): 363-369 (Sept. 1992)
	BS	Konishi et al., Comparison of Protective Immunity Elicited by Recombinant Vaccinia Viruses That Synthesize E or NS1 of Japanese Encephalitis Virus. *Virology* 185: 401-410 (1991)
	BT	Mason et al., Japanese Encephalitis Virus-Vaccinia Recombinants Produce Particulate Forms of the Structural Membrane Proteins and Induce High Levels of Protection against Lethal JEV Infection. *Virology* 180: 294-305 (1991)
	BU	Falgout et al., Immunization of Mice with Recombinant Vaccinia Virus Expressing Authentic Dengue Virus Nonstructural Protein NS1 Protects Against Lethal Dengue Virus Encephalitis. *J. Virol.* 64(9): 4356-4363 (1990)
	BV	Nitayaphan et al., Nucleotide Sequence of the Virulent SA-14 Strain of Japanese Encephalitis Virus and Its Attenuated Vaccine Derivative, SA-14-14-2. *Virology* 177: 541-552 (1990)
	BW	Osatomi and Sumiyoshi, Complete Nucleotide Sequence of Dengue Type 3 Virus Genome RNA. *Virology* 176:643-647 (1990)
	BX	Bray et al., Mice Immunized with Recombinant Vaccinia Virus Expressing Dengue 4 Virus Structural Proteins with or without Nonstructural Protein NS1 Are Protected Against Fatal Dengue Virus Encephalitis. *J. Virol.* 63(6): 2853-2856 (1989)
	BY	Falgout et al., Proper Processing of Dengue Virus Nonstructural Glycoprotein NS1 Requires the N-terminal Hydrophobic Signal Sequence and the Downstream Nonstructural Protein NS2a. *J. Virol.* 63(5): 1852-1860 (1989)
	BZ	Roehrig et al., Synthetic Peptides Derived from the Deduced Amino Acid Sequence of the E-Glycoprotein of Murray Valley Encephalitis Virus Elicit Antiviral Antibody. *Virology* 171: 49-60 (1989)
	CA	Zhang et al., Passive Protection of Mice, Goats, and Monkeys Against Japanese Encephalitis With Monoclonal Antibodies. *J. Med. Virol.* 29: 133-138 (1989)
	CB	Hahn et al. Nucleotide Sequence of Dengue 2 RNA and Comparison of the Encoded Proteins with Those of Other Flaviviruses. *Virology* 162: 167-180 (1988)
	CC	Hashimoto et al. Molecular Cloning and Complete Nucleotide Sequence of the Genome of Japanese Encephalitis Virus Beijing-1 Strain. *Virus Genes* 1(3): 305-317 (1988)
	CD	Osatomi et al., Nucleotide Sequence of Dengue Type 3 Virus Genomic RNA Encoding Viral Structural Proteins. *Virus Genes* 2(1): 99-108 (1988)
	CE	Zhang et al., Immunization of Mice with Dengue Structural Proteins and Nonstructural Protein NS1 Expressed by Baculovirus Recombinant Induces Resistance to Dengue Virus Encephalitis. *J. Virol.* 62(8): 3027-3031(1988)
	CF	Mackow et al., The Nucleotide Sequence of Dengue Type 4 Virus: Analysis of Genes Coding for Nonstructural Proteins. *Virology* 159: 217-228 (1987)
	CG	Sumiyoshi et al. Complete Nucleotide Sequence of the Japanese Encephalitis Virus Genome RNA. *Virology* 161: 497-510 (1987)
	CH	Trent et al., Partial Nucleotide Sequence of St. Louis Encephalitis Virus RNA: Structural Proteins, NS1, ns2a, and ns2b. *Virology* 156: 293-304 (1987)

COPY

	CJ	Zhao et al., Expression of Dengue Virus Structural Proteins and Nonstructural Protein NS1 by a Recombinant Vaccinia Virus. *J. Virol.* 61(12): 4019-4022 (1987)
	CJ	Deubel et al., Nucleotide Sequence and Deduced Amino Acid Sequence of the Structural Proteins of Dengue Type 2 Virus, Jamaica Genotype. *Virology* 155: 365-377 (1986)
	CK	Kimura-Kuroda et al., Antigenic Comparison of Envelope Protein E between Japanese Encephalitis Virus and Some Other Flaviviruses Using Monoclonal Antibodies. *J. Gen. Virol.* 67: 2663-2672 (1986)
	CL	Zhao et al., Cloning Full-Length Dengue Type 4 Viral DNA Sequences: Analysis of Genes Coding for Structural Proteins. *Virology* 155: 77-88 (1986)
	CM	Rice et al., Nucleotide Sequence of Yellow Fever Virus: Implications for Flavivirus Gene Expression and Evolution. *Science* 229: 726-733 (1985)
	CN	Seeger et al., The cloned genome of ground squirrel hepatitis virus is infectious in the animal. *Proc. Natl. Acad. Sci. USA* 81(18): 5849-5852 (Sep 1984)
	CO	Kimura-Kuroda et al., Topographical Analysis of Antigenic Determinants on Envelope Glycoprotein V3 (E) of Japanese Encephalitis Virus, Using Monoclonal Antibodies. *J. Virol.* 45(1): 124-132 (1983)
	CP	Roehrig et al., Identification of Epitopes on the E Glycoprotein of Saint Louis Encephalitis Virus Using Monoclonal Antibodies. *Virology* 128: 118-126 (1983)
	CQ	Hunt and Calisher, Relationships of Bunyamwera Group Viruses by Neutralization. *Amer. J. Trop. Med. Hyg.* 28(4): 740-749 (1979)

EXAMINER:	DATE CONSIDERED: 04/20/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* Reference was not considered because the IDS fails to comply with 37 C.F.R. 1.97 and 1.98.

ATTORNEY DOCKET NO. 14114.033203
SERIAL NO. 09/826,115
Page 1 of 2

COPY

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 7-80) PATENT AND TRADEMARK OFFICE LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)	ATTORNEY DOCKET NO.: 14114.033203	SERIAL NO. 09/826,115
	APPLICANT: Cheng	
	FILING DATE: April 6, 2001	GROUP: Unassigned 1645

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	B1	~~6,165,477~~	~~12/26/00~~	~~Ivy et al.~~			

FOREIGN PATENT DOCUMENTS

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	B2	Alvarez *et al.* A Phase I Study of Recombinant Adenovirus Vector-Mediated Delivery of an Anti-erbB-2 Single-Chain (sFv) Antibody Gene for Previously Treated Ovarian and Extraovarian Cancer Patients. *Hum. Gene Ther. 8:229-242 (January 20, 1997)*
	B3	Selay. The Choice of Carrier. *Synthetic Vaccines Volume I* (edited by Arnon) CRC Press Inc., Boca Raton, FL. pp. 83-92 (1987)
	B4	Clarke *et al.* Techniques For Hemagglutination And Hemagglutination-Inhibition With Arthropod-Borne Viruses. *Amer. J. Trop. Med. and Hyg.* 7:561-573 (1958)
	B5	Gruenberg *et al.* Partial Nucleotide Sequence and Deduced Amino Acid Sequence of the Structural Proteins of Dengue Virus Type 2, New Guinea C and PUO-218 Strains. *J. Gen. Virol.* 69:1391-1398 (1988)
	B6	Heinz *et al.* Flaviviruses. *Immunochemistry of Viruses II: The Basis for Serodiagnosis and Vaccines* (edited by von Regenmortel and Neurath) Elsevier Science Publishers.Chapter 14, pp. 289-305 (1990)
	B7	Henchal *et al.* Dengue Virus-Specific And Flavivirus Group Determinants Identified With Monoclonal Antibodies By Indirect Immunofluorescence. *Amer. J. Trop. Med. Hyg.* 31:830-836 (1982)
	B8	Hubálek *et al.* West Nile Fever--a Reemerging Mosquito-Borne Viral Disease in Europe. *Emerg. Infect. Dis.* 5(5):643-650 (1999)
	B9	Kohler *et al.* Continuous cultures of fused cells secreting antibody of predefined specificity. *Nature* 256:495-497 (August 7, 1975)
	B10	Konishi *et al.* Avipox virus-vectored Japanese encephalitis virus vaccines: Use as vaccine candidates in combination with purified subunit immunogens. *Vaccine* 12(7):633-638 (1994)
	B11	Kozak. Circumstances and Mechanisms of Inhibition of Translation by Secondary Structure in Eucaryotic mRNAs. *Mol. Cell. Biol.* 9(11):5134-5142 (November 1989)
	B12	Laemmli. Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4. *Nature* 277:680-685 (August 15, 1970)

W108821

COPY

	B13	Lai *et al.* Immunization of Monkeys with Baculovirus Recombinant-expressed Dengue Envelope and NS1 Glycoproteins Induces Partial Resistance to Challenge with Homotypic Dengue Virus. In *Vaccines 90: Modern Approaches to New Vaccines Including Prevention of AIDS*, Cold Spring Harbor Laboratory. Cold Springs Harbor, NY pp. 119-124 (1990)
	B14	Mason *et al.* Sequence of the Dengue-1 Virus genome in the Region Encoding the Three Structural Proteins and the Major Nonstructural Protein NS1. *Virology* 161:262-267 (1987)
	B15	Smithburn *et al.* A Neurotropic Virus Isolated From The Blood Of A Native Of Uganda. *Am. J. Trop. Med. Hyg.* 20:471-492 (1940)
	B16	Tardei *et al.* Evaluation of Immunoglobulin M (IgM) and IgG Enzyme Immunoassays in Serologic Diagnosis of West Nile Virus Infection. *J. Clin. Microbiol.* 38(6):2232-2239 (June 2000)
	B17	Tsai *et al.* Japanese Encephalitis Vaccines. In *Vaccines*, (3rd edition) (edited by Plotkin and Orenstein), W.B. Saunders Company, Philadelphia, PA. Chapter 27, pp. 672-710 (1999)
	B18	Tsai et al. Japanese Encephalitis Vaccines. In *Vaccines*, (2nd edition) (edited by Plotkin and Mortimer), W.B. Saunders Co., Philadelphia, PA. Chapter 24, pp. 671-713 (1994)
	B19	Yang *et al.* A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. *Nature* 382:319-324 (July 25, 1996)

EXAMINER:	DATE CONSIDERED: 09/20/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* References were not considered because the IDS fails to comply with 37 C.F.R. 1.97 & 1.98.

ATTORNEY DOCKET NO. 14114.0332U3
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of	:	
Chang	:	
Serial No.: 09/826,115	:	Group Art Unit: Unassigned
Filed: April 4, 2001	:	Examiner: Unassigned _____
For: NUCLEIC ACID VACCINES FOR PREVENTION OF FLAVIVIRUS INFECTION	:	

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

NEEDLE & ROSENBERG, P.C.
Suite 1200, The Candler Building
127 Peachtree Street, N.E.
Atlanta, Georgia 30303-1811

July 27, 2001

Sir:

Submitted herewith on form PTO 1449 is a listing of documents known to applicants and/or their attorneys in compliance with the requirements of 37 C.F.R. § 1.56. A copy of each of these documents is enclosed.

Consideration of the cited documents and making the same of record in the prosecution of the above-noted application are respectfully requested.

Applicants believe that this Information Disclosure Statement is being filed in accordance with 37 C.F.R. § 1.97(b)(3), i.e., before the mailing date of the first Office Action on the merits pertaining to the above-referenced application. Therefore, no fee is believed to be due. However, if a fee is



required, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. 14-0629.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.

Mary L. Miller
Registration No. 39,303

NEEDLE & ROSENBERG, P.C.
Suite 1200, The Candler Building
127 Peachtree Street, N.E.
Atlanta, Georgia 30303-1811
404/688-0770

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date shown below.

Mary L. Miller — Date: July 27, 2001

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 7-80) PATENT AND TRADEMARK OFFICE **LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)**	**ATTORNEY DOCKET NO.:** 14114.0332U3	**SERIAL NO.** 09/826,115
	APPLICANT: Chang	
	FILING DATE: April 4, 2001	**GROUP:** Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,514,375	05/07/96	Paoletti et al.	424	199.1	
	AB	5,494,671	02/27/96	Lai et al.	424	218.1	
	AC	5,229,293	07/20/93	Matsuura et al.	435	320.1	
	AD	5,021,347	06/04/91	Yasui et al.	435	235	
	AE	4,810,492	03/07/89	Fujita et al.	424	88	

FOREIGN PATENT DOCUMENTS

	AF	WO 99/63095	12/09/99	PCT			
	AG	WO 93/06214	04/01/93	PCT			
	AH	WO 92/03545	03/05/92	PCT			
	AI	WO 90/01946	03/08/90	PCT			

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AJ	Abstract, Japanese Patent Publication No. JP 05276941 "Non-infective structure particle preparation, useful as vaccine - by infecting preliminary flavivirus infected cell with cDNA integrated recombinant vaccinia virus, and then separating non-infective structure particles containing E protein of flavivirus," (October 26, 1993)
	AK	Deubel et al., Nucleotide Sequence and Deduced Amino Acid Sequence of the Nonstructural Proteins of Dengue Type 2 Virus, Jamaica Genotype: Comparative Analysis of the Full-Length Genome. *Virol.* 165: 234-244 (1988)
	AL	Davis et al., West Nile Virus Recombinant DNA Vaccine Protects Mouse and Horse from Virus Challenge and Expresses in Vitro a Noninfectious Recombinant Antigen That Can Be Used in Enzyme-linked Immunosorbent Assays. *J. Virol.* 75(9): 4040-4047 (2001) (published on-line April 4, 2001)
	AM	Konishi et al., Generation and Characterization of a Mammalian Cell Line Continuously Expressing Japanese Encephalitis Virus Subviral Particles. *J. Virol.* 75(5): 2204-2212 (2001)
	AN	Asnis et al., The West Nile Virus Outbreak of 1999 in New York: The Flushing Hospital Experience. *Clin. Infect. Dis.* 30: 413-418 (2000)
	AO	Chang et al., A Single Intramuscular Injection of Recombinant Plasmid DNA Induces Protective Immunity and Prevents Japanese Encephalitis in Mice. *J. Virol.* 74(9):4244-4252 (2000)
	AP	Garmendia et al., Recovery and Identification of West Nile Virus from a Hawk in Winter. *J. Clin. Microbiol.* 38(8): 3110-3111 (2000)

	AQ	Johnson et al., Detection of Anti-Arboviral Immunoglobulin G by Using a Monoclonal Antibody-Based Capture Enzyme-Linked Immunosorbent Assay. *J. Clin. Microbiol.* 38(5): 1827-1831 (2000)
	AR	Martin et al., Standardization of Immunoglobulin M Capture Enzyme-Linked Immunosorbent Assays for Routine Diagnosis of Arboviral Infections. *J. Clin. Microbiol.* 38(5): 1823-1826 (2000)
	AS	Update: Surveillance for West Nile Virus in Overwintering Mosquitos --- New York, 2000. *Morb. Mortal. Wkly. Rep.* 49(09): 178-179 (Mar. 10, 2000)
	AT	Update: West Nile Virus Activity --- Northeastern United States, 2000. *Morb. Mortal. Wkly. Rep.* 49(36): 820-822 (Sept. 15, 2000)
	AU	Aberle et al., A DNA Immunization Model Study with Constructs Expressing the Tick-Borne Encephalitis Virus Envelope Protein E in Different Physical Forms. *J. Immunol.* 163: 6756-6761 (1999)
	AV	Anderson et al., Isolation of West Nile Virus from Mosquitoes, Crows, and a Cooper's Hawk in Connecticut. *Science* 286: 2331-2333 (Dec. 17, 1999)
	AW	Azevedo et al., Main features of DNA-based immunization vectors. *Braz. J. Med. Biol. Res.* 32(2): 147-153 (1999)
	AX	Jia et al., Genetic analysis of West Nile New York 1999 encephalitis virus. *Lancet* 354: 1971-1972 (Dec. 4, 1999)
	AY	Lanciotti et al., Origin of the West Nile Virus Responsible for an Outbreak of Encephalitis in the Northeastern United States. *Science* 286: 2333-2337 (Dec. 17, 1999)
	AZ	Mir et al., High-efficiency gene transfer into skeletal muscle mediated by electric pulses. *Proc. Nat. Acad. Sci. USA* 96: 4262-4267 (1999)
	BA	Ho et al. DNA vaccination induces a long-term antibody response and protective immunity against pseudorabies virus in mice. *Arch. Virol.* 143: 115-125 (1998)
	BB	Konishi et al., Induction of Protective Immunity against Japanese Encephalitis in Mice by Immunization with a Plasmid Encoding Japanese Encephalitis Virus Premembrane and Envelope Genes. *J. Virol.* 72(6):4925-4930 (June 1998)
	BC	Kuno et al., Phylogeny of the Genus *Flavivirus*. *J. Virol.* 72(1): 73-83 (Jan. 1998)
	BD	Lin et al., DNA Immunization with Japanese Encephalitis Virus Nonstructural Protein NS1 Elicits Protective Immunity in Mice. *J. Virol.* 72(1): 191-200 (Jan 1998)
	BE	Klinman et al., CpG motifs as immune adjuvants. *Vaccine* 17: 19-25 (1999)
	BF	Kochel et al. Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice. *Vaccine* 15(5): 547-552 (1997)
	BG	Wang et al., Immune Response to Neonatal Genetic Immunization. *Virology* 228: 278-284 (1997)
	BH	Dmitriev et al., Immunization with recombinant vaccinia viruses expressing structural and part of the nonstructural region of tick-borne encephalitis virus cDNA protect mice against lethal encephalitis. *J. Biotechnol.* 44: 97-103 (1996)
	BI	Hennessy et al., Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study. *Lancet* 347: 1583-1586 (1996)
	BJ	Phillpotts et al., Immunization with DNA polynucleotides protects mice against lethal challenge with St. Louis encephalitis virus. *Arch. Virol.* 141: 743-749 (1996)
	BK	Sato et al., Immunostimulatory DNA Sequences Necessary for Effective Intradermal Gene Immunization. *Science* 273: 352-354 (1996)
	BL	Allison et al., Synthesis and Secretion of Recombinant Tick-Borne Encephalitis Virus Protein E in Soluble and Particulate Form. *J. Virol.* 69(9): 5816-5820 (Sept 1995)
	BM	Chen et al., Construction of Intertypic Chimeric Dengue Viruses Exhibiting Type 3 Antigenicity and Neurovirulence for Mice. *J. Virol.* 69(8): 5186-5190 (Aug 1995)

	BN	dos Santos et al., Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213. *Virus Research* 35: 35-41 (1995)
	BO	Venugopal et al., Immunity to St. Louis encephalitis virus by sequential immunization with recombinant vaccinia and baculovirus derived PrM/E proteins. *Vaccine* 13(11): 1000-1005 (1995)
	BP	Mandl et al., Complete Genomic Sequence of Powassan Virus: Evaluation of Genetic Elements in Tick-Borne Versus Mosquito-Borne Flaviviruses. *Virology* 194: 173-184 (1993)
	BQ	Konishi et al., Mice Immunized with a Subviral Particle Containing the Japanese Encephalitis Virus prM/M and E Proteins Are Protected from Lethal JEV Infection. *Virology* 188: 714-720 (1992)
	BR	Wolff et al., Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. *Hum. Mol. Genet.* 1(6): 363-369 (Sept. 1992)
	BS	Konishi et al., Comparison of Protective Immunity Elicited by Recombinant Vaccinia Viruses That Synthesize E or NS1 of Japanese Encephalitis Virus. *Virology* 185: 401-410 (1991)
	BT	Mason et al., Japanese Encephalitis Virus-Vaccinia Recombinants Produce Particulate Forms of the Structural Membrane Proteins and Induce High Levels of Protection against Lethal JEV Infection. *Virology* 180: 294-305 (1991)
	BU	Falgout et al., Immunization of Mice with Recombinant Vaccinia Virus Expressing Authentic Dengue Virus Nonstructural Protein NS1 Protects Against Lethal Dengue Virus Encephalitis. *J. Virol.* 64(9): 4356-4363 (1990)
	BV	Nitayaphan et al., Nucleotide Sequence of the Virulent SA-14 Strain of Japanese Encephalitis Virus and Its Attenuated Vaccine Derivative, SA-14-14-2. *Virology* 177: 541-552 (1990)
	BW	Osatomi and Sumiyoshi, Complete Nucleotide Sequence of Dengue Type 3 Virus Genome RNA. *Virology* 176:643-647 (1990)
	BX	Bray et al., Mice Immunized with Recombinant Vaccinia Virus Expressing Dengue 4 Virus Structural Proteins with or without Nonstructural Protein NS1 Are Protected Against Fatal Dengue Virus Encephalitis. *J. Virol.* 63(6): 2853-2856 (1989)
	BY	Falgout et al., Proper Processing of Dengue Virus Nonstructural Glycoprotein NS1 Requires the N-terminal Hydrophobic Signal Sequence and the Downstream Nonstructural Protein NS2a. *J. Virol.* 63(5): 1852-1860 (1989)
	BZ	Roehrig et al., Synthetic Peptides Derived from the Deduced Amino Acid Sequence of the E-Glycoprotein of Murray Valley Encephalitis Virus Elicit Antiviral Antibody. *Virology* 171: 49-60 (1989)
	CA	Zhang et al., Passive Protection of Mice, Goats, and Monkeys Against Japanese Encephalitis With Monoclonal Antibodies. *J. Med. Virol.* 29: 133-138 (1989)
	CB	Hahn et al. Nucleotide Sequence of Dengue 2 RNA and Comparison of the Encoded Proteins with Those of Other Flaviviruses. *Virology* 162: 167-180 (1988)
	CC	Hashimoto et al. Molecular Cloning and Complete Nucleotide Sequence of the Genome of Japanese Encephalitis Virus Beijing-1 Strain. *Virus Genes* 1(3): 305-317 (1988)
	CD	Osatomi et al., Nucleotide Sequence of Dengue Type 3 Virus Genomic RNA Encoding Viral Structural Proteins. *Virus Genes* 2(1): 99-108 (1988)
	CE	Zhang et al., Immunization of Mice with Dengue Structural Proteins and Nonstructural Protein NS1 Expressed by Baculovirus Recombinant Induces Resistance to Dengue Virus Encephalitis. *J. Virol.* 62(8): 3027-3031(1988)
	CF	Mackow et al., The Nucleotide Sequence of Dengue Type 4 Virus: Analysis of Genes Coding for Nonstructural Proteins. *Virology* 159: 217-228 (1987)
	CG	Sumiyoshi et al. Complete Nucleotide Sequence of the Japanese Encephalitis Virus Genome RNA. *Virology* 161: 497-510 (1987)
	CH	Trent et al., Partial Nucleotide Sequence of St. Louis Encephalitis Virus RNA: Structural Proteins, NS1, ns2a, and ns2b. *Virology* 156: 293-304 (1987)

	CI	Zhao et al., Expression of Dengue Virus Structural Proteins and Nonstructural Protein NS_1 by a Recombinant Vaccinia Virus. *J. Virol.* 61(12): 4019-4022 (1987)
	CJ	Deubel et al., Nucleotide Sequence and Deduced Amino Acid Sequence of the Structural Proteins of Dengue Type 2 Virus, Jamaica Genotype. *Virology* 155: 365-377 (1986)
	CK	Kimura-Kuroda et al., Antigenic Comparison of Envelope Protein E between Japanese Encephalitis Virus and Some Other Flaviviruses Using Monoclonal Antibodies. *J. Gen. Virol.* 67: 2663-2672 (1986)
	CL	Zhao et al., Cloning Full-Length Dengue Type 4 Viral DNA Sequences: Analysis of Genes Coding for Structural Proteins. *Virology* 155: 77-88 (1986)
	CM	Rice et al., Nucleotide Sequence of Yellow Fever Virus: Implications for Flavivirus Gene Expression and Evolution. *Science* 229: 726-733 (1985)
	CN	Seeger et al., The cloned genome of ground squirrel hepatitis virus is infectious in the animal. *Proc. Natl. Acad. Sci. USA* 81(18): 5849-5852 (Sep 1984)
	CO	Kimura-Kuroda et al., Topographical Analysis of Antigenic Determinants on Envelope Glycoprotein V3 (E) of Japanese Encephalitis Virus, Using Monoclonal Antibodies. *J. Virol.* 45(1): 124-132 (1983)
	CP	Roehrig et al., Identification of Epitopes on the E Glycoprotein of Saint Louis Encephalitis Virus Using Monoclonal Antibodies. *Virology* 128: 118-126 (1983)
	CQ	Hunt and Calisher, Relationships of Bunyamwera Group Viruses by Neutralization. *Amer. J. Trop. Med. Hyg.* 28(4): 740-749 (1979)

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ASSISTANT COMMISSIONER FOR PATENTS AND TRADEMARKS 0420

SIR: PLEASE ACKNOWLEDGE RECEIPT OF THE ENCLOSED:

(X) Information Disclosure Statement (2 pages)
(X) Form PTO-1449 (4 pages)
(X) 69 References
(X) Certificate of Mailing: July 27, 2001



IN RE APPLICATION OF: Chang

TITLE: "NUCLEIC ACID VACCINES FOR PREVENTION OF FLAVIVIRUS INFECTION"

SERIAL NO.: 09/826,115 FILED: April 4, 2001

REF. NO.: 14114.0332U3 (MLM/WBD:prt)

ATTORNEY DOCKET NO. 14114.0332U3
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of	:	
Chang	:	Group Art Unit: 1642
Confirmation No. 4134	:	
Serial No. 09/826,115	:	Examiner: Unassigned
Filed: April 4, 2001	:	
For: "NUCLEIC ACID VACCINES FOR PREVENTION OF WEST NILE VIRUS INFECTION AND NONINFECTIOUS ANTIGEN FOR DIAGNOSTIC TEST"	:	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT SUBMITTED IN ACCORDANCE WITH THE PROVISIONS OF 37 C.F.R. §1.97(b)

Commissioner for Patents
Washington, D.C. 20231

NEEDLE & ROSENBERG, P.C.
Suite 1200, The Candler Building
127 Peachtree Street, N.E.
Atlanta, Georgia 30303-1811

February 15, 2002

Sir:

Submitted herewith on Form PTO 1449 is a listing of documents known to applicants and/or their attorneys pursuant to the requirements of 37 C.F.R. §1.56. A copy of each of these documents is enclosed.

Consideration of the cited documents and making the same of record in the prosecution of the above-noted application are respectfully requested.



As these documents are considered to be timely filed, no fee is believed due. However, the Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.

Mary L. Miller

Mary Miller
Registration No. 39,303

NEEDLE & ROSENBERG, P.C.
Suite 1200, The Candler Building
127 Peachtree Street, N.E.
Atlanta, Georgia 30303-1811
404/688-0770

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on the date listed below

Mary L. Miller — Mary Miller

February 15, 2002 — Date

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 7-80) PATENT AND TRADEMARK OFFICE **LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)**	**ATTORNEY DOCKET NO.:** 14114.0332U3	**SERIAL NO.** 09/826,115
	APPLICANT: Chang	
	FILING DATE: April 4, 2001	**GROUP:** Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	B1	6,165,477	12/26/00	Ivy *et al.*			

FOREIGN PATENT DOCUMENTS

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	B2	Alvarez *et al.* A Phase I Study of Recombinant Adenovirus Vector-Mediated Delivery of an Anti-erbB-2 Single-Chain (sFv) Antibody Gene for Previously Treated Ovarian and Extraovarian Cancer Patients. *Hum. Gene Ther. 8:229-242 (January 20, 1997)*
	B3	Selay. The Choice of Carrier. *Synthetic Vaccines Volume I* (edited by Arnon) CRC Press Inc., Boca Raton, FL. pp. 83-92 (1987)
	B4	Clarke *et al.* Techniques For Hemagglutination And Hemagglutination-Inhibition With Arthropod-Borne Viruses. *Amer. J. Trop. Med. and Hyg.* 7:561-573 (1958)
	B5	Gruenberg *et al.* Partial Nucleotide Sequence and Deduced Amino Acid Sequence of the Structural Proteins of Dengue Virus Type 2, New Guinea C and PUO-218 Strains. *J. Gen. Virol.* 69:1391-1398 (1988)
	B6	Heinz *et al.* Flaviviruses. *Immunochemistry of Viruses II: The Basis for Serodiagnosis and Vaccines* (edited by von Regenmortel and Neurath) Elsevier Science Publishers Chapter 14, pp. 289-305 (1990)
	B7	Henchal *et al.* Dengue Virus-Specific And Flavivirus Group Determinants Identified With Monoclonal Antibodies By Indirect Immunofluorescence. *Amer. J. Trop. Med. Hyg.* 31:830-836 (1982)
	B8	Hubálek *et al.* West Nile Fever-a Reemerging Mosquito-Borne Viral Disease in Europe. *Emerg. Infect. Dis.* 5(5):643-650 (1999)
	B9	Kohler *et al.* Continuous cultures of fused cells secreting antibody of predefined specificity. *Nature* 256:495-497 (August 7, 1975)
	B10	Konishi *et al.* Avipox virus-vectored Japanese encephalitis virus vaccines: use as vaccine candidates in combination with purified subunit immunogens. *Vaccine* 12(7):633-638 (1994)
	B11	Kozak. Circumstances and Mechanisms of Inhibition of Translation by Secondary Structure in Eucaryotic mRNAs. *Mol. Cell. Biol.* 9(11):5134-5142 (November 1989)
	B12	Laemmli. Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4. *Nature* 277:680-685 (August 15, 1970)

	B13	Lai *et al.* Immunization of Monkeys with Baculovirus Recombinant-expressed Dengue Envelope and NS1 Glycoproteins Induces Partial Resistance to Challenge with Homotypic Dengue Virus. In *Vaccines 90: Modern Approaches to New Vaccines including Prevention of AIDS*, Cold Spring Harbor Laboratory, Cold Springs Harbor, NY pp. 119-124 (1990)
	B14	Mason *et al.* Sequence of the Dengue-1 Virus genome in the Region Encoding the Three Structural Proteins and the Major Nonstructural Protein NS1. *Virology* 161:262-267 (1987)
	B15	Smithburn *et al.* A Neurotropic Virus Isolated From The Blood Of A Native Of Uganda. *Am. J. Trop. Med. Hyg.* 20:471-492 (1940)
	B16	Tardei *et al.* Evaluation of Immunoglobulin M (IgM) and IgG Enzyme Immunoassays in Serologic Diagnosis of West Nile Virus Infection. *J. Clin. Microbiol.* 38(6):2232-2239 (June 2000)
	B17	Tsai *et al.* Japanese Encephalitis Vaccines. In *Vaccines*, (3rd edition) (edited by Plotkin and Orenstein), W.B. Saunders Company, Philadelphia, PA. Chapter 27, pp. 672-710 (1999)
	B18	Tsai et al. Japanese Encephalitis Vaccines. In *Vaccines*, (2nd edition) (edited by Plotkin and Mortimer), W.B. Saunders Co., Philadelphia, PA. Chapter 24, pp. 671-713 (1994)
	B19	Yang *et al.* A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. *Nature* 382:319-324 (July 25, 1996)

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR: PLEASE ACKNOWLEDGE RECEIPT OF THE ENCLOSED:

__X_ Supplemental Information Disclosure Statement (2 Pages)
__X_ Form PTO-1449 (2 Pages)
__X_ A copy of each cited reference (19 references)
__X_ Certificate of U.S. Mailing dated February 15, 2002

OIPE JC184 MAR 0 1 2002 PATENT & TRADEMARK OFFICE

IN THE NAME(S) OF: Chang
TITLE: " NUCLEIC ACID VACCINES FOR PREVENTION OF WEST NILE VIRUS INFECTION AND NONINFECTIOUS ANTIGEN FOR DIAGNOSTIC TEST"
APPLN. SERIAL NO. 09/826,115 FILING DATE: APRIL 4, 2001
ATTORNEY DOCKET NO.: 14114.0332U3 (MLM/WBD:tmh)

RECEIVED

MAR 1 4 2002

NEEDLE & ROSENBERG

By: ldt Date: 03/15/02
Reviewed: lmh 3/15/02
Name/Init